ARCHIVES

Afinitor and Exemestane More Than Doubles PFS, Reduces Progression Risk by 57 Percent

This article is from The Cancer Letter archive.

Vol. 34 No. 9 | September 30, 2011

Download PDF Visit The Full Archive

Related Articles

IDMC Halts Mekinist-Tafinlar Trial Early Due to OS Benefit; Recommends Crossover

July 25, 2014

In Brief: Reginald Ho Assumes ACS Presidency; Board Calls On NCI To Fully Fund ASSIST Program

November 13, 1992

Sloan-Kettering Cited For 8 Violations Of NY State Standards

November 24, 1995

In Brief: BRCA 2 Gene sequence Published; CALGB To Mark 40th Anniversary

March 8, 1996

In Brief: appropriations Approved; Grants, contracts May Flow Unimpeded; NCI Positions An Issue

December 16, 1977

Gori to Hopkins Part Time, Keeps DCCP Deputy Job

September 1, 1978